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AbstrACt 
Objectives Amyotrophic lateral sclerosis (ALS) is a rapidly 
progressive neurodegenerative disorder. Sleep disturbance 
may interfere with clearance of abnormal proteins that 
aggregate in neurodegenerative diseases. The objective of 
this study was to examine the association between benign 
prostatic hyperplasia (BPH), a common disorder causing 
nocturia and sleep disturbance, and risk of ALS and other 
motor neuron disease (MND). We hypothesised that men 
with BPH, in comparison to men in the general population, 
would be at increased risk.
Design This is a nationwide, population-based cohort 
study.
setting This study was conducted among the population 
of Denmark.
Participants We used linked Danish medical databases to 
identify all men with a first-time diagnosis of BPH between 
1 January 1980 and 30 November 2013 and no prior 
diagnosis of MND (BPH cohort, n=223 131) and an age-
matched general population comparison cohort of men 
without BPH or MND (n=1 115 642).
Primary outcome measure The primary outcome is 
diagnosis of MND after the BPH diagnosis (index) date, 
with follow-up until MND diagnosis, emigration, death or 
30 November 2013.
results We used Cox regression to compute adjusted HR, 
comparing men with and without BPH. After 34 years of 
follow-up, there were 227 cases of MND in the BPH cohort 
(incidence rate 0.13/1000 person-years) and 1094 MND 
cases in the comparison cohort (0.12/1000 person-years; 
HR 1.05, 95% CI 0.90 to 1.22). Risk did not vary by follow-
up time.
Conclusions BPH is not associated with an increased risk 
of ALS and other MND. Future studies should examine the 
relation between other disorders that disrupt sleep and 
MND risk in men and women.
IntrODuCtIOn
Motor neuron disease (MND) includes amyo-
trophic lateral sclerosis (ALS) and closely 
related disorders such as progressive bulbar 
palsy. These are progressive neurodegener-
ative diseases that affect motor neurons in 
the spinal cord, brainstem and cerebrum.1 
Roughly half of patients with ALS die within 
2.5 years of symptoms onset, mainly due to 
respiratory failure, and this illness carries 
a high economic burden.2 3 Most cases are 
sporadic, with onset during middle or old 
age, and men are affected twice as often as 
women.1 Apart from age and sex, there are 
few known risk factors.2 
Similar to several other neurodegenerative 
diseases, MND is characterised by the accu-
mulation of protein aggregates within vulner-
able neurons.1 The glymphatic system of the 
brain is a major pathway for the removal of 
toxic substances within the cerebrospinal 
and interstitial fluids. Its function is similar to 
that of the lymphatic system in the rest of the 
body, and glymphatic flow is increased during 
deep sleep.4 5 Sleep disruption is linked, for 
example, to Alzheimer’s disease, possibly 
through reduced clearance of amyloid-beta,5 6 
strengths and limitations of this study
 ► This is the first study to examine the relation be-
tween a disorder with the potential to disrupt sleep 
on a chronic basis (benign prostatic hyperplasia 
(BPH)) and motor neuron disease (MND).
 ► The exposure (BPH) and outcome (MND) were de-
termined from nationwide, population-based, linked 
medical registries in a country with national health 
service and universal access to care.
 ► The long follow-up and large sample size allow lon-
ger exposure, reduce concerns of reverse causality 
and increase precision of the results.
 ► The validity of the diagnosis of BPH in this population 
is not known; some men diagnosed with BPH may 
not have sleep disruption due to nocturia; some men 
in the general population comparison cohort may 
have had undiagnosed BPH; and some men diag-
nosed with MND may have had a different disorder.
 ► Our analyses were adjusted for factors associated 
with both BPH and MND, but results could have been 
affected by unrecognised confounding.
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a protein that accumulates in the brains of patients with 
Alzheimer's disease. Sleep disruption may also be a risk 
factor for MND,4 but this association has not been previ-
ously investigated.
Benign prostatic hyperplasia (BPH) with lower urinary 
tract symptoms is a common, age-related disorder in 
men, with a lifetime prevalence of about 26%.7 Nocturia, 
defined as two or more voids per night, causes sleep 
deprivation, sleep fragmentation and insomnia.8 Approx-
imately 70% of men with BPH suffer from nocturia.9 
In this study, we sought to evaluate whether there was 
an association between BPH and MND. Since BPH is 
a common, treatable condition that often interrupts 
sleep, an increased risk of MND in this population would 
support a pathogenetic role of sleep disruption in this 
disorder and could have public health implications.
We used Danish population-based medical and admin-
istrative registries with nationwide coverage and long-
term follow-up to examine the association of BPH with 
ALS and other MND. We hypothesised that BPH would 
be associated with increased risk of these disorders.
MethODs
setting and design
Denmark has a tax-funded healthcare system, with 
universal access to general practice and hospital-based 
care.10 Residents are assigned a unique personal identi-
fication number in the Danish Civil Registration System 
at birth or immigration. This number permits accurate 
patient-level linkage of data from all Danish registries.10
bPh cohort
We used the Danish National Patient Registry (DNPR) to 
identify a cohort of all men with a first-time diagnosis of 
BPH, seen as inpatients or outpatients in Danish hospitals 
between 1 January 1980 and 30 November 2013 (the BPH 
cohort). The DNPR has recorded all inpatient diagnoses 
and procedures since 1977 and all outpatient clinic visits 
and emergency room visits since 1995.11 Diagnoses in the 
DNPR were coded according to the International Classifi-
cation of Diseases, 8th revision (ICD-8) from 1977 to 1993 
and 10th revision (ICD-10) since 1994.11 The index date 
was the date of BPH diagnosis.
General population comparison cohort
Using the Danish Civil Registration System, we assembled 
a matched general population comparison cohort of men 
who were alive and without a diagnosis of BPH or ALS 
or other MND at the index date of the corresponding 
patient with BPH. From this pool, we randomly sampled, 
with replacement, up to five men for each man with 
BPH, matching on year of birth (the general population 
comparison cohort).
Outcomes
The outcome of interest was incident MND, based on 
first-time inpatient diagnoses (from 1980 onwards) or 
outpatient hospital diagnoses (from 1995 onwards) in 
the DNPR.
Covariables
Components of the metabolic syndrome are associated 
with risks of both BPH12 13 and MND14 15 and might there-
fore act as confounders or as their markers. We used inpa-
tient and outpatient DNPR records to identify diagnoses 
of diabetes, obesity, hypertension and hyperlipidaemia 
before the index date among the members of both 
cohorts. Diagnostic codes used in this study are given in 
table 1.
statistical analyses
We characterised the BPH cohort and the general popu-
lation comparison cohort with respect to age, index year 
and specified comorbidities. We followed all men from 
their index dates until the diagnosis of MND, emigration, 
death or 30 November 2013, and we calculated incidence 
rates of MND per 1000 person-years in each cohort. 
We used Cox proportional-hazards regression anal-
ysis to compute HRs and associated 95% CIs for MND, 
comparing men with BPH with men in the general popu-
lation comparison cohort, while controlling for age and 
calendar time by study design. In the regression model, 
we adjusted for diagnoses of diabetes, obesity, hyperten-
sion and hyperlipidaemia. We constructed cumulative 
incidence curves, accounting for the competing risk of 
death.
We assessed period effects in stratified analyses 
according to calendar period of BPH diagnosis (before 
1994, ICD-8 coding; 1994 and later, ICD-10 coding). We 
calculated the risk of MND during follow-up of up to 34 
years and also during follow-up times of 0–2, >2–10 and 
>10–34 years. The proportionality-of-hazards assumption 
was deemed fulfilled by inspection of log-log plots in each 
follow-up interval and in both intervals combined.
bias analysis
To test the robustness of the results, we conducted a bias 
analysis. This study was based on patients with a first-time 
Table 1 International Classification of Diseases codes used 
in the study
Diagnosis ICD-8 codes ICD-10 codes
Benign prostatic 
hyperplasia
600 N40.9
Amyotrophic lateral 
sclerosis and other motor 
neuron disease
348 G12.2
Diabetes 249, 250 E10, E11
Obesity 277 E65-E68
Hypertension 400–404 I10-I15, I67.4
Hyperlipidaemia 249, 279.00 E78
ICD-8, International Classification of Diseases, 8th edition; ICD-10, 
International Classification of Diseases, 10th edition.
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diagnosis of BPH made during an inpatient or outpatient 
hospital encounter. However, patients treated solely by 
their general practitioners are not captured in the DNPR. 
For this analysis, we assumed that such patients might 
account for 60% of the total BPH population. Also, we 
recognised that a few patients diagnosed with BPH in the 
DNPR may not have BPH. This potential misclassification 
of BPH status would be non-differential with respect to 
later MND status but could have diluted the observed 
association. Therefore, our bias analysis assumed a 40% 
sensitivity and a 90% specificity for a diagnosis of BPH in 
the DNPR.
All statistical analyses were performed using SAS V.9.4.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for the design or implementation of the 
study. No patients were asked to advise on interpretation 
or writing up of results. We have no plans to disseminate 
results of the research to study participants or relevant 
patient communities.
results
bPh and MnD
Between 1 January 1980 and 30 November 2013, the prev-
alence of BPH was 10.8% among Danish men aged 50 
years and older, based on 221 978 first-time DNPR diag-
noses from an at-risk cumulative population of 2 057 854 
men. A total of 223 131 men (1 752 270 person-years at 
risk) had a first-time diagnosis of BPH, after excluding 
103 men with BPH and a diagnosis of ALS or other 
MND before the index date (figure 1). We identified 
1 115 642 (8 774 610 person-years at risk) matched men 
in the general population comparison cohort (figure 1). 
The median age was 71.6 (IQR 64.5 to 78.1) years in 
both cohorts. The median follow-up time was 6.4 (IQR 
2.7 to 11.6) years in the BPH cohort and 6.6 (IQR 3.0 
to 11.4) years in the general population comparison 
cohort. Table 2 shows characteristics of the men in the 
two cohorts.
Over a follow-up period of up to 34 years, we identi-
fied 227 cases of ALS or other MND in the BPH cohort 
(incidence rate 0.13 (95% CI 0.11 to 0.15) per 1000 
person-years at risk) and 1094 cases of MND among the 
matched members of the general population cohort 
(incidence rate 0.12 (95% CI 0.12 to 0.13) per 1000 
person-years at risk) (table 3). The median age of diag-
nosis for MND was 74.7 years (IQR 68.8 to 79.9 years) 
for men in the BPH cohort and 75.0 years (70.2 to 79.9) 
in the comparison cohort. The cumulative incidence of 
MND over 34 years is shown in figure 2. The 34-year risk 
of MND was 0.16% (95% CI 0.13% to 0.18%) for men in 
the BPH cohort and 0.16% (95% CI 0.15% to 0.17%) for 
men in the general population comparison cohort. The 
adjusted HR was 1.05 (95% CI 0.90 to 1.22). The unad-
justed HR was similar to the adjusted (HR 1.04, 95% CI 
0.89 to 1.21).
After 10 years of follow-up, men with BPH had a similar 
risk of ALS or other MND when compared with men in the 
general population comparison cohort (table 3). When 
stratified by year of BPH diagnosis, we found similar risks 
for men diagnosed with BPH during 1980–1993 and for 
men diagnosed during 1994–2013 (table 3).
bias analysis
The bias analysis that considered misclassification of the 
exposure and outcome yielded an unadjusted HR of 1.10 
Figure 1 Flowchart for the benign prostatic hyperplasia (BPH) cohort and the general population comparison cohort. MND, 
motor neuron disease. 
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(95% CI 0.76 to 1.60), similar to the HR found in our 
primary analysis.
DIsCussIOn
In this nationwide, population-based cohort study, we 
did not find an association between BPH and ALS and 
other MND during follow-up of up to 34 years. The asso-
ciation was notably absent in the follow-up period of 10 
to 34 years, when prolonged nocturia and sleep disrup-
tion from BPH might be expected to have the greatest 
effect on disease risk. Our findings thus do not support 
the hypothesis that BPH increases the risk of MND. These 
results imply that sleep disruption during middle age and 
older age linked to BPH does not substantially increase 
the risk of this neurodegenerative disorder. This research 
involved inhabitants of a developed country where 
economic and health disparities are relatively low, but the 
observed association between BPH and MND should be 
similar in other settings.
MND is characterised by the death of motor neurons, 
preceded by the accumulation of protein aggregates 
within these cells.1 Proteins and other wastes are removed 
from the central nervous system in part via the glymphatic 
system, primarily during sleep. The role of sleep disrup-
tion has been best studied in relation to Alzheimer’s 
disease pathogenesis.5 6 The glymphatic system entails 
the influx of cerebrospinal fluid along the Virchow-Robin 
periarterial spaces driven by pulsations generated by arte-
rial smooth muscle cells, flow through the basal lamina 
surrounding capillaries, the rapid interchange of cerebro-
spinal fluid and interstitial fluid in the perivenous space, 
and efflux through the cervical lymph system.4 5 Our study 
was designed to investigate whether BPH—a common 
medical condition with the propensity to disrupt sleep on 
a chronic basis—is associated with the risk of MND. Our 
null results fail to support this association.
strengths and limitations of the study
Our study has important strengths. We derived risk esti-
mates from a population-based cohort study in a setting 
with a national health service and universal access to 
healthcare, which largely removed referral and diagnostic 
bias. Other strengths of this research include the large 
sample size, longitudinal design, prospective and routine 
accumulation of the data, and complete follow-up.
There are also limitations. Although most men with 
BPH suffer from nocturia,9 which in turn leads to sleep 
deprivation and sleep fragmentation,8 the correspon-
dence between BPH and sleep disturbance is imperfect. 
Also, MND registration by hospital codes may be subject 
to misclassification. A Danish validation study estimated 
Table 2 Descriptive data for men in the benign prostatic hyperplasia cohort and the general population comparison cohort
Benign prostatic hyperplasia cohort General population comparison cohort 
n % n %
Number 223 131 100.0 1 115 642 100.0
Age, years 
  <60 30 305 13.6 151 659 13.6
  60–69 67 920 30.4 339 850 30.5
  70–79 82 734 37.1 413 462 37.1
  80+ 42 172 18.9 210 671 18.9
Index year 
  1980–1994 96 951 43.5 484 752 43.5
  1995–2003 65 893 29.5 329 464 29.5
  2004–2013 60 287 27.0 301 426 27.0
Diabetes 
  No 210 577 94.4 1 068 017 95.7
  Yes 12 554 5.6 47 625 4.3
Obesity
  No 219 348 98.3 1 102 758 98.8
  Yes 3783 1.7 12 884 1.2
Hypertension
  No 201 750 90.4 1 037 374 93.0
  Yes 21 381 9.6 78 268 7.0
Hyperlipidaemia
  No 216 962 97.2 1 089 501 97.7
  Yes 6169 2.8 26 141 2.3
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that 88% of patients coded with MND have ALS (68%) 
or another MND (20%), 8% have Parkinson’s disease and 
4% have no final diagnosis.16 Whereas the validity of a 
BPH diagnosis in our population is unknown, we would 
expect some men in the general population comparison 
cohort to have undiagnosed BPH. Outpatient diagnoses 
by general practitioners are not captured in the DNPR, 
although lower urinary tract symptoms would presumably 
be less severe for men diagnosed solely by general prac-
titioners and nocturia less common. Among Danish men 
aged 50 years and older, the 10.8% prevalence of BPH 
is similar to that reported in the Third National Health 
and Nutrition Examination Survey17 but lower than that 
in some other representative cohorts.18 However, our bias 
analysis showed robust results after correction for poten-
tial exposure misclassification. Nonetheless, misclassifi-
cation of BPH or MND could dilute our HR estimates, 
and we could have failed to detect a modest association, 
if present.
MND is itself associated with poor sleep quality.19 
Although sleep disturbance caused by MND might in 
some instances precede a diagnosis of MND and perhaps 
increase the likelihood of BPH diagnosis, MND is not 
known to have a long presymptomatic phase, and risk 
estimates were not elevated during follow-up intervals 
Table 3 Incidence rates, HRs and associated 95% CIs for ALS and other MND, comparing men in the BPH cohort to men in 
a matched general population cohort
ALS and other MND, N
Incidence rate per 1000 
person-years (95% CI)
HR (95% CI)
Unadjusted Adjusted*
Follow-up period
0–34 years
  Comparison cohort 1094† 0.12 (0.12 to 0.13) Reference Reference
  BPH cohort 227† 0.13 (0.11 to 0.15) 1.04 (0.89 to 1.21) 1.05 (0.90 to 1.22)
0–2 years
  Comparison cohort 246 0.12 (0.11 to 0.14) Reference Reference
  BPH cohort 57 0.14 (0.11 to 0.18) 1.18 (0.89 to 1.58) 1.20 (0.90 to 1.61)
>2–10 years
  Comparison cohort 570 0.12 (0.11 to 0.13) Reference Reference
  BPH cohort 117 0.12 (0.10 to 0.15) 1.07 (0.87 to 1.32) 1.08 (0.88 to 1.33)
>10–34 years
  Comparison cohort 278 0.15 (0.13 to 0.17) Reference Reference
  BPH cohort 53 0.13 (0.10 to 0.17) 0.82 (0.58 to 1.15) 0.82 (0.58 to 1.16)
Year of BPH diagnosis
1980–1993
  Comparison cohort 479 0.11 (0.10 to 0.12) Reference Reference
  BPH cohort 103 0.12 (0.10 to 0.15) 1.07 (0.85 to 1.35) 1.06 (0.84 to 1.34)
1994–2013
  Comparison cohort 615 0.13 (0.12 to 0.15) Reference Reference
  BPH cohort 124 0.14 (0.11 to 0.16) 1.02 (0.83 to 1.25) 1.03 (0.84 to 1.26)
*Adjusted for diagnoses of diabetes mellitus, obesity, hypertension and hyperlipidaemia.
†For ALS and other MND, the most common ICD-8 diagnosis was ALS (156 in the comparison cohort, 42 in the BPH cohort), and the most 
common ICD-10 diagnosis was MND (763 in the comparison cohort, 149 in the BPH cohort). Other ICD-8 diagnoses in these cohorts were 
other and unspecified MND (37), progressive bulbar paralysis (20), progressive spinal paralysis (10) and other progressive muscular atrophy 
(2). Other ICD-10 diagnoses were ALS (129), progressive bulbar paralysis (8), progressive spinal paralysis (2), Duchenne-Aran muscular 
atrophy (2) and progressive spinal muscular atrophy (1).
ALS, amyotrophic lateral sclerosis; BPH, benign prostatic hyperplasia; ICD-8, International Classification of Diseases, 8th edition; ICD-10, 
International Classification of Diseases, 10th edition; MND, motor neuron disease.
Figure 2 Cumulative incidence of amyotrophic lateral 
sclerosis and other motor neuron disease in the benign 
prostatic hyperplasia cohort and in the general population 
comparison cohort.
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of >2–10 or >10–34 years. We adjusted our estimates for 
individual diagnoses related to the metabolic syndrome, 
which may be associated with both BPH and MND. Phys-
ical activity is a well-known but controversial risk factor 
for ALS.2 20 We were unable to adjust for this directly, but 
we adjusted for obesity, which in turn is linked to physical 
activity. We are unaware of other shared risk factors, but 
as in any observational study, our results could be affected 
by unrecognised confounding.
Comparison with other studies
We are unaware of other studies that have examined the 
relation between sleep disruption and ALS and other MND.
Implications and conclusions
We found no evidence of an increased risk of ALS and 
other MND among men with diagnosed BPH compared 
with men from the general population. This finding implies 
that sleep disruptions resulting from nocturnal awakenings 
in middle-age and older men with BPH are not substantially 
associated with risk of MND. However, several factors could 
have biased associations towards the null. The validity of a 
BPH diagnosis in the Danish population is not known; some 
men in the general population comparison cohort may 
have had undiagnosed BPH; and some men diagnosed with 
MND may have had some other disorder. Estimates from 
our bias analysis, however, showed results similar to those of 
our primary analysis. Future studies should examine other 
causes of sleep disruption in relation to MND risk in both 
men and women.
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